BRKR Bruker Corporation

Discovery Partners International, Inc. and Bruker AXS Inc. Announce New Bench Top Protein Crystallization System SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (NASDAQ:DPII) and Bruker AXS Inc., a subsidiary of Bruker BioSciences Corporation (NASDAQ:BRKR), together announced the launch of a bench top version of their popular CRYSTAL FARM(TM) product for high-throughput protein crystallization at the 2005 Pittsburgh Conference in Orlando. The new CRYSTAL FARM CF-150 employs the same technology as the CF-400 model in a smaller footprint. The Crystal Farm products have become a market leader in protein crystallization and imaging for the drug discovery and high throughput crystallography community. The Crystal Farm is a fully integrated web-based incubation and imaging system used for protein crystallization screening and optimization. By providing high-throughput protein crystallization automation, Crystal Farm addresses the critical quest for high-speed structure-based drug discovery and design. The bench top system combines capacity for up to 15,000 simultaneous experimental conditions, with DPI's patent pending "Cool Flash" imaging technology, and includes a web-browser based interface that controls all system functions either locally or remotely, including priority-based image scheduling, viewing and scoring. Experimental results stored in a SQL database can be easily mined for monitoring and optimizing crystallization experiments. "The strategic partnership between Discovery Partners and Bruker AXS has allowed us to provide powerful crystallization and X-ray diffraction solutions to the drug discovery and structural biology communities," said John Lillig, CTO & Vice President of Discovery Partners International. "The technological leadership of the Crystal Farm, together with Bruker's expertise and marketing presence in X-ray crystallography, has allowed the Crystal Farm to establish a strong position in this dynamic new market." "The Crystal Farm product has become very popular in large, high-throughput labs, where it produces better quality crystals, more quickly than traditional manual crystallization techniques. We are excited to introduce the bench top model which will make this technology accessible for innovative new applications in smaller-scale laboratories as well," said Dr. Roger Durst, Vice President of R&D and Global Crystallography Business Manager of Bruker AXS. Pittcon 2005, the 56th Pittsburgh Conference and Exposition on Analytical Chemistry and Applied Spectroscopy, is being held from February 27 through March 4 in the Orange County Convention Center. The product introduced here will be exhibited at the Bruker booth #3176. About Discovery Partners Discovery Partners International, Inc. is a leader in drug discovery collaborations. DPI offers integrated services, products, and systems that span the drug discovery continuum, including target characterization, targeted and screening-library design and synthesis, high throughput and high content screening, lead generation and optimization, gene expression analysis, and protein crystallization. DPI has actively contributed to dozens of drug discovery collaborations, working on many of the most promising new biological target areas for the biotech and pharmaceutical industries. Discovery Partners International is headquartered in San Diego, California and has operations in the United States and Europe. For more information on Discovery Partners International, Inc., please visit the Company's website at http://www.discoverypartners.com/. Statements in this press release with respect to Discovery Partners or its business or products that are not strictly historical are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a high degree of risk and uncertainty. Discovery Partners' actual results may differ materially from those projected in the forward looking statements due to risks and uncertainties that exist in Discovery Partners' operations, development efforts and business environment, including risks relating to customer adoption of Discovery Partners products (including Crystal Farm products), the ability of Discovery Partners and Bruker AXS to achieve the goals of their strategic alliance, Discovery Partners' ability to establish and maintain strategic alliances with third parties, the trend toward consolidation of the pharmaceutical industry, technological advances by competitors, and other risks and uncertainties more fully described in Discovery Partners' annual report on Form 10-K for the year ended December 31, 2003 as filed with the Securities and Exchange Commission and Discovery Partners' other SEC reports. About Bruker Biosciences Bruker Biosciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit http://www.bruker-biosciences.com/ Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to Bruker Biosciences' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of Bruker Biosciences' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. DATASOURCE: Discovery Partners International, Inc. CONTACT: John Lillig, CTO & Vice President, +1-858-228-4113, or Craig Kussman, CFO, +1-858-228-4113, both of Discovery Partners International, ; or Roger Durst, Vice President of R&D, +1-608-276-3066, or Michael Willett, P.R. & Investor Relations Officer, +1-978-663-3660 ext. 1411, , both of Bruker AXS Inc. Web site: http://www.bruker-biosciences.com/ Web site: http://www.discoverypartners.com/

Copyright